Ultragenyx Pharmaceu Beats

Ultragenyx Pharmaceu (RARE) reported a 2nd Quarter June 2025 loss of $1.17 per share on revenue of $166.5 million. The consensus estimate was a loss of $1.27 per share on revenue of $161.7 million. The Earnings Whisper number was for a loss of $1.30 per share. Revenue grew 13.2% on a year-over-year basis.

Ultragenyx Pharmaceutical Inc is a development-stage biopharmaceutical company engaged in identifying, acquiring, developing and marketing novel products for the treatment of rare and ultra-rare disease.